Schistosoma Mansoni: the Identification of Some Highly Immunogenic Surface Antigens of the Lung Stage Larvae as Promising Vaccine Candidates Against Schistosomiasis | ||||
| Bulletin of Egyptian Society for Physiological Sciences | ||||
| Article 12, Volume 31, Issue 2, June 2011, Page 157-166 PDF (373.51 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/besps.2011.36129 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| Samir Mahgoub* | ||||
| Department of Biochemistry, Faculty of Medicine, Al Minia University | ||||
| Abstract | ||||
| Background: Schistosomiasis is a global health problem caused by several species of schistosome blood flukes. It is endemic in 74 developing countries; 200 million people are infected worldwide, causing an estimated 200.000 deaths / year. Chemotherapy, although effective, it does not prevent re-infection, and in addition, partial drug resistance may occur. This is why the development of long - lasting immunity through vaccination may be the real solution to control the spread of the disease. Objective: The molecules on the surface or associated with the tegument of the lung stage (7- days schistosomules) of Schistosoma mansoni (S. mansoni) are the major target in the present study as potential vaccine candidates. Materials and methods: Nonidet P- 40 (NP-40) extracted soluble surface proteins of 7-days schistosomules were subjected to 12.5% Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis (SDS-PAGE). The separated surface proteins were electrotransfered onto a nitrocellulose membrane (PVDF), then, western blotting was performed. The non specific binding sites on the membrane were blocked by 1% non-fat dry milk in phosphate buffered saline (PSB), then, the membrane was incubated with pooled sera (primary antibody) collected from S. mansoni chronically infected patients and absorped to E. coli lysate. Anti-rabbit IgG conjugated with alkaline phosphatase was used as the secondary antibody. Results: A number of different immunogenic extracted surface antigens of 7-days schistosomules have been identified by the antibodies in the sera of S. mansoni chronically infected patients of different molecular weights, 18 kDa, 28 kDa, 33 kDa, 38 kDa, 40 kDa, 42 kDa, 45 kDa, 50 kDa, 62 kDa, 66 kDa, 81 kDa and 116 kDa. In conclusion: Progress in schistosome genome research has offered a unique chance to move rapidly from genome sequences to vaccine development. Proteins bound to the surface of parasites are potential vaccine candidates, or they can be used for diagnosis. In the present study, twelve surface proteins of the lung stage larva of S. mansoni with different degrees of immunogenicity are identified; any one of these proteins could be a promising vaccine candidate for S. mansoni. | ||||
|
Statistics Article View: 62 PDF Download: 65 |
||||
